TAKEDA PHARMACEUTICAL CO LTDTT

TAKEDA PHARMACEUTICAL CO LTD

27.41EURD
+0.07+0.26%
Last update at Feb 27, 17:14 GMT
EUR
No tradesPre-market
See on Supercharts

TKD fundamentals

Key facts

Market capitalization‪43.86 B‬EUR
Founded1781
Employees (FY)‪49.28 K‬
CEOChristophe Weber
Websitetakeda.com
About

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Ownership
‪‪1.59 B‬‬
Free Float shares
‪‪1.55 B‬‬ (97.67%)
Closely held shares
‪‪36.97 M‬‬ (2.33%)
Free Float shares
‪‪1.55 B‬‬ (97.67%)
Closely held shares
‪‪36.97 M‬‬ (2.33%)
Capital structure
Market cap
‪‪43.86 B‬‬
Debt
‪‪29.74 B‬‬
Minority interest
‪‪5.63 M‬‬
Cash & equivalents
‪‪3.04 B‬‬
Enterprise value
‪‪70.57 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪43.86 B‬‬
Price to earning ratio (P/E)
32.82x
Price to sales ratio (P/S)
1.52x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
32.82x
Price to sales ratio (P/S)
1.52x
Valuation ratios
‪0.00‬
‪0.40‬
‪0.80‬
‪1.20‬
‪1.60‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪12.00‬
‪24.00‬
‪36.00‬
‪48.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−3.5%‬
‪0.0%‬
‪3.5%‬
‪7.0%‬
‪10.5%‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−2.50 B‬‬
‪0.00‬
‪‪2.50 B‬‬
‪‪5.00 B‬‬
‪‪7.50 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪2.00 B‬‬
‪‪4.00 B‬‬
‪‪6.00 B‬‬
‪‪8.00 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪2.00 B‬‬
‪‪4.00 B‬‬
‪‪6.00 B‬‬
‪‪8.00 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2023
Gastroenterology
Plasma-derivatives Therapies Immunology
Neuroscience
Rare Genetics and Other
Oncology
Other
Rare Hematology
By country
Period: 2023
United States
Europe and Canada
Japan
Asia
Latin America
Other
Russia / Commonwealth of Independent States

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪2.00 B‬‬
‪‪4.00 B‬‬
‪‪6.00 B‬‬
‪‪8.00 B‬‬
Actual
Estimate
Earnings
Next:May 8, 2025
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪−0.40‬
‪−0.20‬
‪0.00‬
‪0.20‬
‪0.40‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
145.53%
Payout ratio (TTM)
Dividend yield TTM
4.45%
Next payment
0.629
Next ex-date
Mar 28, 2025
Dividend history
‪4.0%‬
‪4.4%‬
‪4.8%‬
‪5.2%‬
‪5.6%‬
2019
2020
2021
2022
2023
‪0.00‬
‪0.40‬
‪0.80‬
‪1.20‬
‪1.60‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪‪9.00 B‬‬
‪‪18.00 B‬‬
‪‪27.00 B‬‬
‪‪36.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪20.00 B‬‬
‪‪40.00 B‬‬
‪‪60.00 B‬‬
‪‪80.00 B‬‬
Assets
Liabilities